Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa

Abstract Many papers documented that Parkinson's disease (PD) patients treated with levodopa (l-dopa) shows elevated plasma homocysteine (Hcy) levels. Several lifestyle factors are able to influence plasma Hcy levels. We review the evidence that l-dopa therapy is related with an increase in plasma Hcy levels and that several behaviours could be able to cause changes in plasma Hcy concentrations. Therefore, there are reasons to suggest that a healthy lifestyle lowering Hcy may prevent this potential iatrogenic complication during l-dopa therapy. Moreover, at present, no controlled prospective studies have evaluated this phenomenon.

[1]  T. Bottiglieri Folate, vitamin B12, and neuropsychiatric disorders. , 2009, Nutrition reviews.

[2]  J. Iwamoto,et al.  Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. , 2005, The American journal of medicine.

[3]  G. De Sarro,et al.  Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. , 2005, Pharmacological research.

[4]  J. Burnett,et al.  Alcohol-associated severe hyperhomocysteinaemia , 2005, Annals of clinical biochemistry.

[5]  A. Hofman,et al.  Methylenetetrahydrofolate reductase C677T genotype and PD , 2005, Annals of neurology.

[6]  J. Rodés,et al.  Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics. , 2005, Alcoholism, clinical and experimental research.

[7]  P. Livrea,et al.  Hyperhomocysteinemia in l‐dopa treated Parkinson's disease patients: effect of cobalamin and folate administration , 2005, European journal of neurology.

[8]  S. Westphal,et al.  Effect of drugs on homocysteine concentrations. , 2005, Seminars in vascular medicine.

[9]  H. Hendriks,et al.  Kinetics of homocysteine metabolism after moderate alcohol consumption. , 2005, Alcoholism, clinical and experimental research.

[10]  P. Livrea,et al.  Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. , 2005, Parkinsonism & related disorders.

[11]  P. O'Suilleabhain,et al.  Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[12]  A. Chetrit,et al.  Life-style habits and homocysteine levels in an elderly population , 2004, Aging clinical and experimental research.

[13]  D. Panagiotakos,et al.  Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C-->T mutation on homocysteine concentrations in healthy adults: the ATTICA Study. , 2004, The American journal of clinical nutrition.

[14]  A. Lang,et al.  Homocysteine and levodopa , 2004, Neurology.

[15]  J. Pérez-Castrillón,et al.  Homocysteine as a predictive factor for hip fracture in older persons. , 2004, The New England journal of medicine.

[16]  L. Husemoen,et al.  Effect of lifestyle factors on plasma total homocysteine concentrations in relation to MTHFR(C677T) genotype. Inter99 (7) , 2004, European Journal of Clinical Nutrition.

[17]  A. Siniscalchi [Hyperhomocysteinemia in neurologic diseases]. , 2004, Recenti progressi in medicina.

[18]  P. O'Suilleabhain,et al.  Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. , 2004, Archives of neurology.

[19]  A. Hofman,et al.  Homocysteine levels and the risk of osteoporotic fracture. , 2004, The New England journal of medicine.

[20]  S. Vollset,et al.  Changes in lifestyle and plasma total homocysteine: the Hordaland Homocysteine Study. , 2004, The American journal of clinical nutrition.

[21]  M. Katan,et al.  A healthy lifestyle lowers homocysteine, but should we care? , 2004, The American journal of clinical nutrition.

[22]  A. Di Rocco,et al.  Effect of l-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status , 2004, Neurology.

[23]  D. Nyholm,et al.  New developments in levodopa therapy , 2004, Neurology.

[24]  K. Nakashima,et al.  Levodopa‐induced hyperhomocysteinaemia in Parkinson's disease , 2003, Acta neurologica Scandinavica.

[25]  Jiang He,et al.  Relationship between Cigarette Smoking and Novel Risk Factors for Cardiovascular Disease in the United States , 2003, Annals of Internal Medicine.

[26]  D. Woitalla,et al.  Benefit of folic acid supplementation in parkinsonian patients treated with levodopa , 2003, Journal of neurology, neurosurgery, and psychiatry.

[27]  K. Nakashima,et al.  Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with l-DOPA, homocysteine, and MTHFR genotype , 2003, Journal of the Neurological Sciences.

[28]  H. Blom,et al.  Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease , 2002, Pharmacological Reviews.

[29]  T. Müller,et al.  Dopaminergic substitution in Parkinson’s disease , 2002, Expert opinion on pharmacotherapy.

[30]  D. Cook,et al.  Homocysteine levels in men and women of different ethnic and cultural background living in England. , 2002, Atherosclerosis.

[31]  M. Mattson,et al.  Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease , 2002, Journal of neurochemistry.

[32]  D. Wald,et al.  Randomized trial of folic acid supplementation and serum homocysteine levels. , 2001, Archives of internal medicine.

[33]  G. Coetzee,et al.  Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. , 2001, The American journal of clinical nutrition.

[34]  Yoshihiro Sato,et al.  Risk factors for hip fracture among elderly patients with Parkinson’s disease , 2001, Journal of the Neurological Sciences.

[35]  M. Katan,et al.  Heavy coffee consumption and plasma homocysteine: a randomized controlled trial in healthy volunteers. , 2000, The American journal of clinical nutrition.

[36]  R. Diaz-Arrastia,et al.  Homocysteine and neurologic disease. , 2000, Archives of neurology.

[37]  P. Finglas Dietary Reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline , 2000 .

[38]  L. Wang,et al.  Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid. , 2000, Molecular genetics and metabolism.

[39]  I. Ziv,et al.  Levodopa – an exotoxin or a therapeutic drug? , 2000, Journal of Neurology.

[40]  R. D'Agostino,et al.  Nonfasting Plasma Total Homocysteine Levels and Stroke Incidence in Elderly Persons: The Framingham Study , 1999, Annals of Internal Medicine.

[41]  M. Hennerici,et al.  Homocysteine in cerebral macroangiography and microangiopathy , 1999, The Lancet.

[42]  H. Blom,et al.  Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials , 1998, BMJ.

[43]  I. Crombie Book Review: Non-Random Reflections on Health Services Research , 1997 .

[44]  J. Selhub,et al.  The effect of L-dopa administration and folate deficiency on plasma homocysteine concentrations in rats , 1997 .

[45]  B. Shukitt-Hale,et al.  Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. , 1997, Clinical neuropharmacology.

[46]  A. Spiro,et al.  Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. , 1996, The American journal of clinical nutrition.

[47]  S. Vollset,et al.  Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. , 1995, JAMA.

[48]  K. Perry,et al.  Tropolone antagonism of the l−dopa‐induced elevation of S‐adenosylhomocysteine: S‐adenosylmethionine ratio but not depletion of adrenaline in rat hypothalamus , 1984, The Journal of pharmacy and pharmacology.

[49]  J. Aita,et al.  Why patients with Parkinson's disease fall. , 1982, JAMA.

[50]  H. Taufek,et al.  Influence of exogenous L-3,4,-dihydroxyphenylalanine (L-dopa) on the methionine and s-adenosylmethionine concentrations in the brain and other tissues [proceedings]. , 1980, Biochemical Society transactions.

[51]  R. Wurtman,et al.  Folic acid deficiency and methyl group metabolism in rat brain: effects of L-dopa. , 1974, Archives of Biochemistry and Biophysics.

[52]  G. Defazio,et al.  Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions , 2005, Clinical chemistry and laboratory medicine.

[53]  D. Woitalla,et al.  MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. , 2004, Journal of neural transmission. Supplementum.

[54]  R. Diaz-Arrastia,et al.  Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. , 2003, Archives of neurology.

[55]  R. Steegers-Theunissen,et al.  Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial 1–3 , 2022 .

[56]  J. Selhub,et al.  Homocysteine and thrombotic disease. , 1997, Blood.

[57]  J. Selhub,et al.  The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. , 1992, The American journal of clinical nutrition.